HAE — Haemonetics Corporation stock price, charts and financials

QT72Haemonetics Corporation

Haemonetics Corporation (NYSE: HAE) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
86.79
+1.25+1.46%
HAEQT72Haemonetics Corporation·NYSE
86.79+1.46%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E41.93EPS (ttm)2.04Insider Own2.41%Shs Outstand45.45MPerf Week8.58%
Market Cap3.89BForward P/E14.96EPS next Y5.72Insider Trans0.00%Shs Float44.86MPerf Month14.28%
Enterprise Value4.87BPEG-EPS next Q-Inst Own-Short Float6.02%Perf Quarter42.35%
Income95.63MP/S2.91EPS this Y158.24%Inst Trans-Short Ratio3.02Perf Half Y29.68%
Sales1.33BP/B4.97EPS next Y9.60%ROA4.06%Short Interest2.70MPerf YTD6.72%
Book/sh-P/C13.48EPS next 5Y12.21%ROE11.32%52W High88.60 -2.04%Perf Year12.76%
Cash/sh-P/FCF14.93EPS past 3/5Y-2.91% 5.75%ROIC8.69%52W Low48.01 80.77%Perf 3Y-8.28%
Dividend Est.-EV/EBITDA17.37Sales past 3/5Y4.50% 8.92%Gross Margin57.34%Volatility3.06% 3.14%Perf 5Y44.84%
Dividend TTM-EV/Sales3.65EPS Y/Y TTM-38.97%Oper. Margin18.15%ATR (14)2.67Perf 10Y187.43%
Dividend Ex-Date-Quick Ratio1.87Sales Y/Y TTM-2.06%Profit Margin7.29%RSI (14)74.03Recom2.48
Dividend Gr. 3/5Y-Current Ratio2.95EPS Q/Q8.40%SMA209.11%Beta0.52Target Price80.33
Payout0.00%Debt/Eq1.54Sales Q/Q4.53%SMA5014.78%Rel Volume0.89Prev Close85.54
Employees3,009LT Debt/Eq1.53EarningsAug 06SMA20026.48%Avg Volume887.89KPrice86.79
IPO DateMay 10, 1991Option/ShortYes / YesEPS/Sales Surpr.1.36% 2.83%Net Debt/EBITDA3.49Volume789,605Change1.46%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedMizuhoOutperform$70$85
May-22-26UpgradeB of A SecuritiesNeutralBuy
May-12-26ReiteratedBarrington ResearchOutperform$94$89
May-08-26ReiteratedRobert W. Baird$72$67
Apr-13-26ReiteratedMizuhoOutperform$80$70
Feb-06-26ReiteratedRobert W. Baird$99$81
Feb-06-26ReiteratedMizuhoOutperform$90$80
Feb-06-26ReiteratedBarrington ResearchOutperform$93$94
Feb-02-26ReiteratedBarrington ResearchOutperform$93$94
Jan-12-26ReiteratedBarrington ResearchOutperform$93
Latest News
Jul-30-26
Jul-28-26
Jul-27-26
Jul-24-26
Jul-23-26
Jul-20-26
Jul-14-26
Jul-08-26
Jul-03-26
Jun-26-26
Jun-25-26
Jun-17-26
Jun-15-26
Company

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
3/28/2026
FY 2025
3/29/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue1,3331,3341,3611,3091,169993870988968
Cost of Goods Sold Incl. D&A570590582597546462442501550
Gross Profit764744779712623531428488418
Selling, General and Administrative Excl. Other332442422421374332264266298
Research and Development596069635955413936
Other Operating Expense13206663346334790
Operating Income242241222165156819010384
Interest Expense242910131517171610
Unusual Expense
Non-Operating Income (Expense)-89-850000000
Net Income Before Taxes12812821215214164738774
Income Taxes313144342620-71119
Consolidated Net Income989716811811543797755
Net Income From Continuing Operations989716811811543797755
Net Income989716811811543797755
EPS (Recurring)2.042.053.312.322.270.851.571.511.07
EPS (Basic, Before Extraordinaries)2.042.053.312.322.270.851.571.511.07
EPS (Diluted)2.022.053.312.292.240.841.551.481.04
EBITDA280312356295252192184258193
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio42.9726.3619.0937.2736.9475.2671.6267.3484.12
Price To Sales Ratio3.001.902.323.333.613.256.515.144.70
Gross Margin57.3155.7757.2454.3953.2953.4749.2049.3943.18
Operating Margin18.1518.0716.3112.6113.348.1610.3410.438.68
Net Margin7.357.2712.349.019.844.339.087.795.68
Shares Outstanding464750515151515152
Market Capitalization3,9922,5403,1604,3534,2203,2245,6625,0834,549
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$93.08$80.25$67.42$54.58$41.75 Close Price0.00K24.70K49.39K74.09K98.78KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
KROLL MARK WDirectorNov 10 '25Buy70.561,40098,78424,757Nov 12
Strong Stewart WPresident, Global HospitalJul 26 '24Sale91.154,312393,03918,196Jul 29
Lingamneni AnilaEVP, Chief Technology OfficerJul 12 '24Sale90.00797,11021,331Jul 15
Lingamneni AnilaEVP, Chief Technology OfficerJul 11 '24Sale90.002,136192,24021,410Jul 15
Simon, ChristopherPresident & CEOJun 06 '24Option Exercise41.64104,5164,352,046433,877Jun 07
Basil Michelle LEVP and General CounselMay 29 '24Sale88.0812,9901,144,20931,257May 29
Strong Stewart WPresident, Global HospitalMay 29 '24Sale87.538,857775,25318,196May 29
Llorens JosepEVP, Global ManufacturingMay 20 '24Sale95.0898793,84421,310May 21
Basil Michelle LEVP and General CounselMay 20 '24Sale95.081,604152,50831,257May 21
Strong Stewart WPresident, Global HospitalMay 20 '24Option Exercise56.572,241126,77320,437May 21
Strong Stewart WPresident, Global HospitalMay 20 '24Sale95.1168665,24518,196May 21
Basil Michelle LEVP and General CounselMay 17 '24Sale95.001,073101,93529,352May 21
Llorens JosepEVP, Global ManufacturingMay 17 '24Sale94.8282277,94216,350May 21
Strong Stewart WPresident, Global HospitalMay 16 '24Option Exercise57.602,410138,81618,018May 17
Strong Stewart WPresident, Global HospitalMay 16 '24Sale96.0473370,39715,608May 17
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.